相关实验视频

Updated: Sep 13, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

循环生物标志物在患有渐进性纤维化间歇性肺病的患者中,接受任天达尼布治疗:试点研究

Vitale Miceli¹, Adriana Callari², Elisa Calzolari²

¹Department of Research, IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Via Tricomi 5, Palermo, 90127, Italy. vmiceli@ismett.edu.

Scientific reports

|July 27, 2025

概括

五种血生物标志物 (IGFBP2,PTX3,LGALS1,LGALS9和MMP2) 在忍者达尼布治疗期间显示了渐进性纤维化间歇性肺病 (PF-ILDs) 的动态变化,有助于纤维化监测. 这些生物标志物可能为疾病进展提供预后价值.

科学领域:

肺部医学肺部医学
生物标志物发现发现
纤维化研究纤维化研究

背景情况:

渐进性纤维化间歇性肺病 (PF-ILDs) 由于其无情的进展和有限的治疗选择,构成了重大的临床挑战.
对于监测纤维化和PF-ILD治疗疗效的可靠生物标志物至关重要.
目前对PF-ILDs的诊断和预后工具需要加强以指导临床决策.

研究的目的:

识别和验证与PF-ILDs相关的循环血生物标志物.
为了研究这些生物标志物的动态变化,在用 nintedanib.抗纤维治疗期间.
评估已识别的生物标志物在监测疾病进展和治疗反应方面的潜力.

主要方法:

对127种假定纤维化生物标志物进行了血蛋白质组分析.
纵向分析追踪了PF-ILD患者的生物标志物变化,超过12个月的宁泰达尼布治疗.
使用接收器操作特征 (ROC) 和主要组件分析 (PCA) 来评估生物标志物的诊断和预测值.

主要成果:

七个候选生物标志物表现出高诊断价值 (AUC > 0.7).
五个生物标志物 (IGFBP2,PTX3,LGALS1,LGALS9,MMP2) 在忍丹尼布治疗期间表现出显著的动态变化,与改善的肺功能相关.
随着时间的推移,LGALS1,IGFBP2,PTX3和MMP2的预测价值越来越高,这表明它们在监测纤维化进展中的有用性.

结论:

在PF-ILD患者的抗纤维素治疗期间,五种血生物标志物 (IGFBP2,PTX3,LGALS1,LGALS9,MMP2) 的度发生变化.
这些生物标志物对监测纤维化进展和治疗反应具有潜在的预后价值.
在更大的患者队伍中进行进一步验证是有必要的,以确定临床效用.

更多相关视频

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...